US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

0.6300

-0.0050-0.79%

Post-market: 0.64000.0100+1.59%19:38 EDT

Volume:449.77K

Turnover:300.50K

Market Cap:2.21M

PE:-0.02

High:0.7321

Open:0.6410

Low:0.6290

Close:0.6350

52wk High:60.00

52wk Low:0.6253

Shares:3.50M

Float Shares:1.25M

Volume Ratio:1.17

T/O Rate:35.98%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-32.4560

EPS(LYR):-371.2241

ROE:-126.98%

ROA:-62.31%

PB:0.22

PE(LYR):0.00

Loading ...

Overview Company News Filings

Propanc Biopharma - to Initiate Phase 1B Prp Study in February 2027 for up to 50 Patients

THOMSON REUTERS

Propanc Biopharma - Issues Comparative Analysis of Prp vs Daraxonrasib and Eras-0015

THOMSON REUTERS

Propanc Biopharma Plans Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors Starting February 2027

Propanc Biopharma to Initiate World-First Phase 1B First-in-Human Study of Prp in February 2027

THOMSON REUTERS

Propanc Biopharma Plans First-in-Human Phase 1b PRP Trial Start in February 2027

Propanc Biopharma announces new preclinical data for PRP in PDAC

Propanc Biopharma Says PRP Cuts Pancreatic Tumor Growth by over 90% in Preclinical Models

Propanc Biopharma - Plans Phase 1B Study in 40–45 Patients with Advanced Solid Tumors, Clinical Trial Application Expected in Coming Months

THOMSON REUTERS

Propanc Biopharma - Prp Reduces Metastatic Burden in Liver and Peritoneum in Preclinical Models

THOMSON REUTERS

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for Prp Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

THOMSON REUTERS

Propanc Biopharma Issues 3.5 Million Restricted Shares to Executives, Directors, Service Providers

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Propanc Biopharma Plans First-in-Human Phase 1b Trial of PRP in up to 40 Advanced Solid Tumor Patients

Propanc Biopharma Plans Phase 1b Study of PRP Proenzyme Therapy in Advanced Solid Tumors

Propanc Biopharma - to File Phase 1B Clinical Trial Application for Prp in Advanced Cancer in Q4

THOMSON REUTERS

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

Propanc Biopharma Accelerates Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors

Propanc Biopharma - Prp Shows Reduced Metastatic Burden in Liver and Peritoneum

THOMSON REUTERS

Propanc Biopharma - Prp Extends Median Overall Survival by over 2.5-Fold in Animal Models

THOMSON REUTERS

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% TUMOR Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/PPCB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.63,"timestamp":1789675200000,"preClose":0.635,"halted":0,"volume":449767,"hourTrading":{"tag":"盘后","latestPrice":0.64,"preClose":0.63,"latestTime":"19:38 EDT","volume":16979,"amount":10912.291238599999,"timestamp":1789688287745,"change":0.01,"changeRate":0.015873,"amplitude":0.031746},"delay":0,"changeRate":-0.007874015748031503,"floatShares":1250100,"shares":3503100,"eps":-32.455997,"marketStatus":"Post-Mkt","change":-0.005,"latestTime":"09-17 19:50:56 EDT","open":0.641,"high":0.7321,"low":0.629,"amount":300501.63832512,"amplitude":0.162362,"askPrice":0.6999,"askSize":300,"bidPrice":0.63,"bidSize":238,"shortable":0,"etf":0,"ttmEps":-32.455997,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789689600000},"marketStatusCode":4,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.635,"preHourTrading":{"tag":"盘前","latestPrice":0.6649,"preClose":0.635,"latestTime":"09:26 EDT","volume":38629,"amount":26696.7916175,"timestamp":1789651601668,"change":0.0299,"changeRate":0.047087,"amplitude":0.165354},"postHourTrading":{"tag":"盘后","latestPrice":0.64,"preClose":0.63,"latestTime":"19:38 EDT","volume":16979,"amount":10912.291238599999,"timestamp":1789688287745,"change":0.01,"changeRate":0.015873,"amplitude":0.031746},"volumeRatio":1.170065},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":1250100,"roa":"-62.31%","roe":"-126.98%","lyrEps":-371.224075,"volumeRatio":1.170065,"shares":3503100,"dividePrice":0,"high":0.7321,"amplitude":0.162362,"preClose":0.635,"low":0.629,"week52Low":0.6253,"pbRate":"0.22","week52High":60,"institutionHeld":0,"latestPrice":0.63,"committee":-0.115242,"eps":-32.455997,"divideRate":0,"volume":449767,"delay":0,"ttmEps":-32.455997,"open":0.641,"prevYearClose":13.415,"prevWeekClose":0.921,"prevMonthClose":1.35,"prevQuarterClose":1.5,"fiveDayClose":0.9428,"twentyDayClose":1.14,"sixtyDayClose":1.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-09-16","current":-0.019411,"percent":0.562044,"low":-1.336323,"twenty":-0.269509,"median":-0.125329,"eighty":-0.041422,"high":-0.023125,"avg":-0.180477,"sd":0.190159,"marketCap":1868264},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208},{"date":"2026-08-28","current":-0.276716,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"marketCap":5080767},{"date":"2026-09-04","current":-0.12657,"twenty":-0.273833,"median":-0.12719,"eighty":-0.041245,"marketCap":2323938},{"date":"2026-09-11","current":-0.11699,"twenty":-0.269509,"median":-0.12657,"eighty":-0.041322,"marketCap":2148048},{"date":"2026-09-16","current":-0.101752,"twenty":-0.269509,"median":-0.125329,"eighty":-0.041422,"marketCap":1868264}],"updateTime":1789689056357},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667983739","title":"Propanc Biopharma - to Initiate Phase 1B Prp Study in February 2027 for up to 50 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2667983739","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667983739?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:37","pubTimestamp":1789562255,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4580E1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667983732","title":"Propanc Biopharma - Issues Comparative Analysis of Prp vs Daraxonrasib and Eras-0015","url":"https://stock-news.laohu8.com/highlight/detail?id=2667983732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667983732?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:37","pubTimestamp":1789562255,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4580E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667983268","title":"Propanc Biopharma Plans Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors Starting February 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667983268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667983268?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:33","pubTimestamp":1789561986,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans Phase 1b first-in-human PRP trial in advanced solid tumors starting February 2027Propanc Biopharma outlined plans to start a first-in-human Phase 1b study of PRP in February 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL3BZyGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4112","BK4588","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","BK4139","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","BCDF","NDAQ","IE00BQXX3F31.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4585","LU2095319765.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666335565","title":"Propanc Biopharma to Initiate World-First Phase 1B First-in-Human Study of Prp in February 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666335565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666335565?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:33","pubTimestamp":1788957231,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666353353","title":"Propanc Biopharma Plans First-in-Human Phase 1b PRP Trial Start in February 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666353353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666353353?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:32","pubTimestamp":1788957148,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans first-in-human Phase 1b PRP trial start in February 2027Propanc Biopharma plans to start a Phase 1b first-in-human study of PRP in February 2027 in Australia.No clinical result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDLbVXWJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","BK4112","BK4585","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","BK4588","NDAQ","IE00BKPKM429.USD","BK4139","SG9999014039.USD","SG9999014005.SGD","SG9999014013.SGD","PPCB","LU2095319765.USD","LU0314104364.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BCDF","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700133","title":"Propanc Biopharma announces new preclinical data for PRP in PDAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700133?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:45","pubTimestamp":1787834733,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced new preclinical and early translational data for PRP in pancreatic ductal adenocarcinoma, or PDAC. In orthotopic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-announces-new-preclinical-data-for-prp-in-pdac-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-announces-new-preclinical-data-for-prp-in-pdac-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707660","title":"Propanc Biopharma Says PRP Cuts Pancreatic Tumor Growth by over 90% in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707660","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707660?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833847,"startTime":"0","endTime":"0","summary":"Propanc Biopharma says PRP cuts pancreatic tumor growth by over 90% in preclinical modelsPropanc reported new preclinical PDAC data for PRP showing >90% mean tumor growth inhibition versus vehicle con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL9Rq3jF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4139","BK4588","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014039.USD","BCDF","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014013.SGD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014021.USD","BK4585","PPCB","SG9999014005.SGD","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707678","title":"Propanc Biopharma - Plans Phase 1B Study in 40–45 Patients with Advanced Solid Tumors, Clinical Trial Application Expected in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707678?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707658","title":"Propanc Biopharma - Prp Reduces Metastatic Burden in Liver and Peritoneum in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707658?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662070763","title":"Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for Prp Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2662070763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662070763?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661261985","title":"Propanc Biopharma Issues 3.5 Million Restricted Shares to Executives, Directors, Service Providers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661261985","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661261985?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:01","pubTimestamp":1787306484,"startTime":"0","endTime":"0","summary":"Propanc Biopharma issues 3.5 million restricted shares to executives, directors, service providersPropanc Biopharma board resolutions dated July 24, 2026 were executed via majority shareholder written","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL85S1XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660608394","title":"Propanc Biopharma starts finalization of clinical trial protocol for PRP study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660608394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660608394?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:50","pubTimestamp":1787057418,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its fir...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4139","IDNA","PPCB","NVIB","HYLG","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446786","title":"Propanc Biopharma Plans First-in-Human Phase 1b Trial of PRP in up to 40 Advanced Solid Tumor Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446786","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660446786?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:32","pubTimestamp":1787056337,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans first-in-human Phase 1b trial of PRP in up to 40 advanced solid tumor patientsPropanc Biopharma began finalizing plans for a first-in-human Phase 1b study of PRP in up to 40 ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL7Y8rDm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00BQXX3D17.EUR","BK4585","BK4112","LU0314104364.USD","IE00BQXX3F31.USD","BK4588","SG9999014021.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","PPCB","NDAQ","SG9999014039.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BCDF","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658397776","title":"Propanc Biopharma Plans Phase 1b Study of PRP Proenzyme Therapy in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2658397776","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658397776?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:46","pubTimestamp":1786538783,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans Phase 1b study of PRP proenzyme therapy in advanced solid tumorsPropanc outlined PRP, a once-weekly IV combination of trypsinogen and chymotrypsinogen, as a differentiation-bas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL1QJjyz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658779079","title":"Propanc Biopharma - to File Phase 1B Clinical Trial Application for Prp in Advanced Cancer in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2658779079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658779079?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:36","pubTimestamp":1786538212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490OW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163740","title":"Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163740?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:51","pubTimestamp":1786024283,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma, one of th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-reports-new-preclinical-data-for-prp-in-pancreatic-ductal-adenocarcinoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-reports-new-preclinical-data-for-prp-in-pancreatic-ductal-adenocarcinoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363163","title":"Propanc Biopharma Accelerates Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363163","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363163?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:36","pubTimestamp":1786019818,"startTime":"0","endTime":"0","summary":"Propanc Biopharma accelerates Phase 1b first-in-human PRP trial in advanced solid tumorsPropanc Biopharma on Aug. 6, 2026 flagged new preclinical, early translational PRP data in pancreatic cancer mod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL117tCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631800","title":"Propanc Biopharma - Prp Shows Reduced Metastatic Burden in Liver and Peritoneum","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631800?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631388","title":"Propanc Biopharma - Prp Extends Median Overall Survival by over 2.5-Fold in Animal Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631388?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657386631","title":"Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% TUMOR Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2657386631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657386631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}]}}